BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...
BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...
BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...
University of Toronto researchers have discovered nine new genes used by bacteria to protect themselves against ...
The phage bank-derived monophage or sur-mesure cocktails are equivalent to personalized phage therapy as mentioned ... of constraints imposed by drug regulation and typical medical practice.
New insights into a "friendly virus" that could pave the way for cutting-edge treatments for the potentially fatal superbug C ...
The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...
Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' trials predating Fleming's discovery of penicillin by approximately a decade. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback